April 7, 2023
JCR Pharmaceuticals has decided to tap the firepower of Sumitomo Pharma to jointly promote Izcargo (pabinafusp alfa), a treatment for mucopolysaccharidosis type II, known as Hunter syndrome, in Japan. The two companies announced their copromotion deal on April 6. Under...read more